Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC

Ann Oncol. 2014 Oct;25(10):2092. doi: 10.1093/annonc/mdu257. Epub 2014 Jul 17.

Authors

C Leduc¹, B Besse²

Affiliations

¹ Department of Chest Diseases, Strasbourg University Hospital, Strasbourg. Electronic address: [email protected].
² Department of Cancer Medicine, Gustave Roussy, Villejuif, France.

PMID: 25035277
DOI: 10.1093/annonc/mdu257

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Anaplastic Lymphoma Kinase
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / genetics
Carcinoma, Non-Small-Cell Lung / pathology
Clinical Trials as Topic
Crizotinib
Disease Progression
ErbB Receptors / antagonists & inhibitors
ErbB Receptors / genetics
Humans
Protein Kinase Inhibitors / administration & dosage
Pyrazoles / administration & dosage*
Pyridines / administration & dosage*
Receptor Protein-Tyrosine Kinases / antagonists & inhibitors
Receptor Protein-Tyrosine Kinases / genetics*

Substances

Protein Kinase Inhibitors
Pyrazoles
Pyridines
Crizotinib
ALK protein, human
Anaplastic Lymphoma Kinase
EGFR protein, human
ErbB Receptors
Receptor Protein-Tyrosine Kinases